Published in J Virol on September 24, 2008
Parvovirus B19 uptake is a highly selective process controlled by VP1u, a novel determinant of viral tropism. J Virol (2013) 0.91
Chloroquine and its derivatives exacerbate B19V-associated anemia by promoting viral replication. PLoS Negl Trop Dis (2010) 0.87
Human Parvoviruses. Clin Microbiol Rev (2017) 0.84
The globoside receptor triggers structural changes in the B19 virus capsid that facilitate virus internalization. J Virol (2010) 0.83
Characterization of the early steps of human parvovirus B19 infection. J Virol (2012) 0.81
Presence of IgG anti-gp160/120 antibodies confers higher HIV capture capacity to erythrocytes from HIV-positive individuals. PLoS One (2012) 0.77
Coat as a dagger: the use of capsid proteins to perforate membranes during non-enveloped DNA viruses trafficking. Viruses (2014) 0.76
Severe warm autoimmune haemolytic anaemia due to anti-Jk(a) autoantibody associated with Parvovirus B19 infection in a child. Blood Transfus (2013) 0.75
The VP1u Receptor Restricts Parvovirus B19 Uptake to Permissive Erythroid Cells. Viruses (2016) 0.75
Parvovirus-like particles in human sera. Lancet (1975) 7.11
Outbreak of aplastic crises in sickle cell anaemia associated with parvovirus-like agent. Lancet (1981) 4.62
Human parvovirus, the cause of erythema infectiosum (fifth disease)? Lancet (1983) 4.41
Erythrocyte P antigen: cellular receptor for B19 parvovirus. Science (1993) 4.12
Intrauterine parvovirus infection associated with hydrops fetalis. Lancet (1984) 3.99
A viral phospholipase A2 is required for parvovirus infectivity. Dev Cell (2001) 3.97
Human parvovirus-associated arthritis: a clinical and laboratory description. Lancet (1985) 3.82
Early interactions between poliovirus and ERK cells: some observations on the nature and significance of the rejected particles. Virology (1962) 2.79
The VP1 capsid protein of adeno-associated virus type 2 is carrying a phospholipase A2 domain required for virus infectivity. J Gen Virol (2002) 2.44
Studies on the in vitro uncoating of poliovirus. II. Characteristics of the membrane-modified particle. Virology (1977) 2.22
Immune response to B19 parvovirus and an antibody defect in persistent viral infection. J Clin Invest (1989) 2.08
Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteins. J Virol (1999) 1.97
Parvoviral virions deploy a capsid-tethered lipolytic enzyme to breach the endosomal membrane during cell entry. Proc Natl Acad Sci U S A (2005) 1.85
A conformational change in the adeno-associated virus type 2 capsid leads to the exposure of hidden VP1 N termini. J Virol (2005) 1.79
Characterization of capsid and noncapsid proteins of B19 parvovirus propagated in human erythroid bone marrow cell cultures. J Virol (1987) 1.77
Parvovirus B19 infection and autoimmune disease. Autoimmun Rev (2003) 1.61
Controlled conformational transitions in the MVM virion expose the VP1 N-terminus and viral genome without particle disassembly. Virology (1999) 1.60
Early events in poliovirus infection: virus-receptor interactions. Proc Natl Acad Sci U S A (1996) 1.58
The VP1 N-terminal sequence of canine parvovirus affects nuclear transport of capsids and efficient cell infection. J Virol (2002) 1.52
P blood group regulation of glycosphingolipid levels in human erythrocytes. J Biol Chem (1979) 1.48
Kinetic analysis of the effect of poliovirus receptor on viral uncoating: the receptor as a catalyst. J Virol (2001) 1.46
Alpha5beta1 integrin as a cellular coreceptor for human parvovirus B19: requirement of functional activation of beta1 integrin for viral entry. Blood (2003) 1.45
Neutralizing linear epitopes of B19 parvovirus cluster in the VP1 unique and VP1-VP2 junction regions. J Virol (1993) 1.45
Complementary roles of multiple nuclear targeting signals in the capsid proteins of the parvovirus minute virus of mice during assembly and onset of infection. J Virol (2002) 1.42
The VP1 unique region of parvovirus B19 and its constituent phospholipase A2-like activity. J Virol (2002) 1.42
Release of canine parvovirus from endocytic vesicles. Virology (2003) 1.41
Ku80 autoantigen as a cellular coreceptor for human parvovirus B19 infection. Blood (2005) 1.29
Interfacial enzymology of parvovirus phospholipases A2. J Biol Chem (2004) 1.28
Recombinant human parvovirus B19 vectors: erythrocyte P antigen is necessary but not sufficient for successful transduction of human hematopoietic cells. J Virol (2001) 1.17
The ubiquitin-proteasome machinery is essential for nuclear translocation of incoming minute virus of mice. Virology (2004) 1.15
Antiphospholipid antibodies in pediatric and adult patients with rheumatic disease are associated with parvovirus B19 infection. Arthritis Rheum (2003) 1.12
Conformational changes in the VP1-unique region of native human parvovirus B19 lead to exposure of internal sequences that play a role in virus neutralization and infectivity. J Virol (2006) 1.02
Peptides derived from the unique region of B19 parvovirus minor capsid protein elicit neutralizing antibodies in rabbits. Virology (1995) 1.00
The VP1-unique region of parvovirus B19: amino acid variability and antigenic stability. J Gen Virol (2001) 0.99
A murine monoclonal IgM antibody specific for blood group P antigen (globoside) Br J Haematol (1986) 0.93
Identification of an immunodominant peptide in the parvovirus B19 VP1 unique region able to elicit a long-lasting immune response in humans. Viral Immunol (2001) 0.92
Parvovirus B19 infection in pregnancy. J Obstet Gynaecol Can (2002) 0.92
The association of VP1 unique region protein in acute parvovirus B19 infection and anti-phospholipid antibody production. Clin Chim Acta (2006) 0.90
Induction of antiphospholipid antibodies and antiphospholipid syndrome-like autoimmunity in naive mice with antibody against human parvovirus B19 VP1 unique region protein. Clin Chim Acta (2007) 0.87
Parvovirus B19 does not bind to membrane-associated globoside in vitro. Virology (2005) 0.86
Osmotic properties of human erythrocytes treated by phospholipase A2 from bee venom. Br J Haematol (1987) 0.77
The ubiquitin-proteasome machinery is essential for nuclear translocation of incoming minute virus of mice. Virology (2004) 1.15
Cytoplasmic trafficking of minute virus of mice: low-pH requirement, routing to late endosomes, and proteasome interaction. J Virol (2002) 1.13
Prion removal capacity of plasma protein manufacturing processes: a data collection from PPTA member companies. Transfusion (2012) 1.06
Conformational changes in the VP1-unique region of native human parvovirus B19 lead to exposure of internal sequences that play a role in virus neutralization and infectivity. J Virol (2006) 1.02
Robustness of solvent/detergent treatment of plasma derivatives: a data collection from Plasma Protein Therapeutics Association member companies. Transfusion (2009) 0.97
Stability of minute virus of mice against temperature and sodium hydroxide. Biologicals (2003) 0.92
Parvovirus uncoating in vitro reveals a mechanism of DNA release without capsid disassembly and striking differences in encapsidated DNA stability. Virology (2005) 0.92
Parvovirus B19 uptake is a highly selective process controlled by VP1u, a novel determinant of viral tropism. J Virol (2013) 0.91
Sodium hydroxide renders the prion protein PrPSc sensitive to proteinase K. J Gen Virol (2003) 0.88
Chloroquine and its derivatives exacerbate B19V-associated anemia by promoting viral replication. PLoS Negl Trop Dis (2010) 0.87
Different susceptibility of B19 virus and mice minute virus to low pH treatment. Transfusion (2004) 0.86
Molecular mechanism underlying B19 virus inactivation and comparison to other parvoviruses. Transfusion (2007) 0.84
The globoside receptor triggers structural changes in the B19 virus capsid that facilitate virus internalization. J Virol (2010) 0.83
Characterization of the early steps of human parvovirus B19 infection. J Virol (2012) 0.81
Prevalence of equine herpesvirus types 2 and 5 in horse populations by using type-specific PCR assays. Vet Res (2002) 0.80
Contribution to safety of immunoglobulin and albumin from virus partitioning and inactivation by cold ethanol fractionation: a data collection from Plasma Protein Therapeutics Association member companies. Transfusion (2011) 0.79
Virus safety of intravenous immunoglobulin: future challenges. Clin Rev Allergy Immunol (2005) 0.78
Impaired genome encapsidation restricts the in vitro propagation of human parvovirus B19. J Virol Methods (2013) 0.77
Functional integrity of intravenous immunoglobulin following irradiation with a virucidal dose of gamma radiation. Biologicals (2004) 0.77